Healthcare Industry News: Atrial Septal Defect
News Release - January 29, 2009
AGA Medical Corporation Begins Proceedings Against Occlutech to Recover DamagesMINNEAPOLIS, Jan. 29 -- (Healthcare Sales & Marketing Network) -- AGA Medical Corporation (AGA) today announced that, following its previously announced favorable patent infringement final ruling by the German court of appeals over Occlutech GmbH of Jena, Germany (Occlutech), it has calculated and notified Occlutech of the amount of damages that it will seek from Occlutech based on the court's ruling. After learning that Occlutech has terminated all manufacturing and sales and that its CEO has resigned, AGA has started proceedings in the insolvency court in Germany to protect AGA's claims for damages.
About AGA Medical Corporation
AGA Medical Corporation, based in Plymouth, Minnesota, is a leader in developing interventional devices for the minimally invasive treatment of cardiovascular defects and peripheral vascular disease. Founded in 1995 by Dr. Kurt Amplatz, a former professor and researcher at the University of Minnesota Department of Radiology, AGA develops and commercializes devices for a range of structural heart repair and circulatory conditions. Several of these devices have been major innovations in the treatment of the most common congenital "holes in the heart", such as Atrial Septal Defects and patent foramen ovales.
More than 700 articles have been published in medical literature that support the benefits of AGA devices, including improved patient outcomes, reduced length of stay, and accelerated recovery times for the patient. AGA devices have received regulatory approval and are marketed in 101 countries. For more information, visit http://www.amplatzer.com.
Source: AGA Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.